Noventra Pharma TirReta (60mg Self-Mix – Tirzepatide + Retatrutide Stack)

TirReta is a combination formulation supplied in a lyophilized (self-mix) format, requiring reconstitution prior to use. It combines tirzepatide, a dual incretin receptor agonist, with retatrutide, a multi-receptor peptide investigated for activity at glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.

This combination is investigated for its role in metabolic and endocrine signalling pathways related to energy balance, glucose regulation, and regulatory processes.

Key Features:

• 60mg combined formulation: tirzepatide + retatrutide

• Dual + multi-receptor activity: GLP-1, GIP, and glucagon receptor pathways

• Lyophilized (self-mix) format requiring reconstitution

• Investigated for roles in metabolic and endocrine signalling pathways

• Studied in relation to energy balance and glucose regulation processes

• Associated in research with metabolic pathway modulation

Suggested Use:
For research or controlled clinical use only. Protocols vary depending on study design and should be determined by qualified professionals in an appropriate setting.

Storage:

• Unreconstituted (lyophilized): Store in a cool, dry place (15–25°C), protected from light. Refrigeration (2–8°C) may be used for extended stability

• After reconstitution: Store at 2–8°C. Do not freeze

• Avoid repeated freeze–thaw cycles

• Use within a limited timeframe once reconstituted (based on formulation stability)

Important Information:
This product contains investigational components and should be handled and used within appropriate research or clinical frameworks under qualified supervision. Tirzepatide has been studied in clinical settings for specific indications, while retatrutide remains under investigation. Not recommended for individuals under 18, pregnant or breastfeeding individuals, or those with certain medical conditions. Ensure compliance with applicable regulations prior to use.